Democratic Republic of the Congo (the)

in page functions
[French]
Congo Democratic Republic of the
Total population (2017) 82,242,537
Birth cohort (2017) 3,351,364
Surviving Infants (surviving to 1 year per year, 2017) 3,127,787
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 75/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 98/1000
World Bank Index, IDA (2015) 3.00
Gross Nation Income (per capita US$, 2015) 410
Co-financing group (2017) Initial self-financing
No. of districts/territories (2015) 517

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Congo Democratic Republic of the

Type of support

Approvals

2001-2021 (US$)
(25 Apr 2017)

Commitments

2001-2021 (US$)
(25 Apr 2017)

Disbursements

2000-2017 (US$)
(25 Apr 2017)

% Disbursed

(25 Apr 2017)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $737,197,516 $875,923,229 $684,869,628
Civil Society Organisation support (CSO) $9,767,601 $9,767,601 $9,867,601 101%
Cold Chain Equipment Optimisation Platform (CCEOP) $13,357,326 $13,357,326
Health system strengthening (HSS 1) $56,814,000 $56,814,000 $56,814,000 100%
Health system strengthening (HSS 2) $111,302,940 $144,991,152 $79,743,904 72%
Immunisation services support (ISS) $25,807,280 $25,807,280 $25,807,280 100%
Injection Safety Devices (NVS) $1,529,500 $4,170,000 $1,856,428 121%
Injection safety support (INS) $2,713,931 $2,713,931 $2,713,931 100%
IPV (NVS) $9,880,227 $9,880,227 $8,696,222 88%
Measles SIA (NVS) $11,898,926 $11,898,926 $11,710,012 98%
Measles SIA - Operational costs (OPC) $20,274,500 $20,274,500 $20,274,500 100%
Meningitis A - campaign (NVS) $13,744,023 $13,744,023 $13,744,023 100%
Meningitis A - operational costs (OPC) $11,645,500 $11,645,500 $11,645,500 100%
Penta (NVS) $171,177,252 $192,410,252 $165,207,120 97%
Pneumo (NVS) $226,452,618 $299,989,118 $224,204,403 99%
Product Switch Grant (PSG) $350,425 $350,425 $350,425 100%
Tetra DTP-HepB (NVS) $10,357,601 $10,357,601 $10,357,601 100%
Vaccine Introduction Grant (VIG) $5,070,500 $5,070,500 $5,070,500 100%
Yellow Fever (NVS) $35,053,366 $42,680,866 $36,806,178 105%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Congo Democratic Republic of the DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2015)

Grade of confidence


N/A
DTP3 - Official country estimates (2015) 94%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2012) 60.00%
Household survey: DTP3 coverage for female (2012) 61.10%
Household survey: Last DTP3 survey (2012) 61%
% districts achieving > 80% DTP3 coverage (2015) 86%
% districts achieving < 50% DTP3 coverage (2015) 1%
MCV WHO/UNICEF estimates (2015) 79%

Breakdown of support

Non-vaccine support Vaccine support
31% 69%
$212,287,641 $472,581,987

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Congo Democratic Republic of the

10 November 2016

Tanzania

Measles jab saves over 20 million young lives in 15 years, but hundreds of children still die of the disease every day

Measles outbreaks in numerous countries – caused by gaps in routine immunisation and in mass vaccination campaigns – continue to be a serious challenge.

19 September 2016

Stockpiling

On the frontline: Gavi's support to fragile states

With more than half of Gavi-supported countries officially listed as fragile states, Gavi is increasingly working on several fronts to ensure vaccines still reach people living on the frontlines of humanitarian crises.

17 March 2016

Nusarat, a young Pakistani mother, waiting to get her child vaccinated.

Immunisation as the gateway to health: why women hold the key in Pakistan

Gavi’s Deputy CEO Anuradha Gupta reflects on gender-related barriers to immunisation in Pakistan

close icon

modal window here